Nigel SheailGlobal Head, Mergers & Acquisitions and Business Development & Licensing at Novartis
Nigel Sheail is Global Head of Mergers & Acquisitions and Business Development & Licensing since September 1st, 2017 and joined Novartis in 2015 as Head of Business Development & Licensing. He is a member of the Financial Leadership Team.
Prior to joining Novartis, Nigel was Head of Business Development and Licensing for Bayer Healthcare. He also served as Head of Group M&A at Roche and Head of Licensing for their Pharma division.
Nigel has been responsible for a broad range of healthcare deals from research and technology collaborations through to large M&A transactions. Academically trained as a molecular biologist, Nigel is a qualified Chartered Accountant and has held a number of functions within the Pharmaceutical industry at Bayer, Roche and GSK.
In addition to his work in business development, Nigel has also worked as a global controller for research and was finance director responsible for the establishment of Roche’s operations in China which included five joint venture operating companies and a holding company. Nigel was the founding treasurer of the Swiss Pharma Licensing Group.
Nigel holds a Bachelor of Science degree in Molecular Biology with high honors from the University of Edinburgh, School of Biological Sciences and an ACA degree, ICAEW Chartered Accountant qualification.